
Publication
Controlled Goods Data: Overview of the Regulatory Framework
The Controlled Goods Program (“CGP”) is Canada’s domestic industrial security program, which regulates the examination, possession, and transfer of controlled goods.
With this issue, I am pleased to have the opportunity to congratulate my partner and co-head of the Norton Rose Fulbright restructuring group, Scott Atkins, on an extremely successful three-year term as president of INSOL International. INSOL is the leading global organization of insolvency professionals.
Scott was instrumental in developing a comprehensive strategic review of INSOL through the landmark INSOL 2030 Strategic Plan and by leading several new future-shaping initiatives to enable INSOL to continue to serve its members in the decade to come.
Scott led the INSOL conferences in London 2022, in Tokyo 2023 and, most recently, in San Diego 2024. These were milestone events for INSOL, including celebrating INSOL’s 40th anniversary and driving membership growth to a record 12,300 members from over 108 countries.
As the co-leader of our Restructuring group, Scott provides a fantastic global perspective to help us advise our clients through these turbulent times. Scott’s clear and strategic leadership will be invaluable as the world realigns around geopolitical and technological disruption.
Good reading,
Howard Seife
Global Co-Head of Restructuring
New York
Publication
The Controlled Goods Program (“CGP”) is Canada’s domestic industrial security program, which regulates the examination, possession, and transfer of controlled goods.
Publication
On August 25, 2025, the Government of Alberta publicly re-affirmed its interest in nuclear energy with the launch of its Nuclear Energy Engagement (the Engagement).
Publication
Health Canada has proposed a major change to the regulation of biosimilar drugs that may accelerate biologic patent litigation in Canada. Following the lead of other jurisdictions, Health Canada has proposed that biosimilar manufacturers no longer be required to conduct phase 3 clinical trials to enter the Canadian market.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2025